...Yohei Mikami; Junya Tsunoda; Shohei Suzuki; Ichiro Mizushima; Hiroki Kiyohara; Takanori Kanai Background: Two major types of 5-aminosalicylic acid (5-ASA)-containing preparations, namely, mesalazine/5-ASA and sulfasalazine (SASP), are currently used as first-line therapy for ulcerative colitis...

...Maartje M. van de Meeberg; Johannes P.D. Schultheiss; Bas Oldenburg; Herma H. Fidder; Alwin D.R. Huitema Background: Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for treating mild-to-moderate ulcerative colitis (UC). Unfortunately a significant group...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2019 Mesalazine Crohn’s disease Ulcerative colitis Thiopurines, such as azathioprine and 6-mercaptopurine, are key drugs in maintenance therapy for inflammatory...

...M.P. Connolly; C.D. Poole; C.J. Currie; P. Marteau; S.K. Nielsen Background/Aim: To investigate patient-reported health-related quality of life (HRQoL) in data collected from a multinational randomized double-blind controlled trial comparing oral mesalazine (4 g) + topical mesalazine enema (1 g...

... activity (Harvey-Bradshaw Index) or laboratory indicators of inflammation. No serious adverse reactions occurred. 5-Amino-salicylic acid Pentasa® Mesalazine Crohn’s disease Digestion 1990;45:88-92 © 1990 S. Kargcr AG, Basel 0012-2823/90/0452-0088S2.75/0 Slow-Release 5-Amino...

.... Smoking is one of the most important risk factors for postoperative recurrence. Preoperative disease activity and the severity of endoscopic lesions in the neoterminal ileum within the first postoperative year are predictors of symptomatic recurrence. Mesalazine is generally the first-line treatment used...

...;s disease Maintenance treatment Mesalazine Azathioprine Methotrexate Infliximab Of patients with Crohn’s disease who have not previously undergone surgical treatment, and who are in symptomatic remission, 25–50% will experience symptom recurrence within 2 years [ 1, 2 ]. Because...

.... In the same study, rifaximin was compared with mesalazine, an anti-inflammatory compound widely used in the treatment of inflammatory bowel disease, which showed comparable efficacy. As expected, addition of mesalazine to rifaximin did exert a synergistic effect [ 29 ], most likely because the two drugs...